GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Patrys Ltd (ASX:PAB) » Definitions » Growth Rank

Patrys (ASX:PAB) Growth Rank : 0 (As of Apr. 10, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Patrys Growth Rank?

Patrys has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Patrys Growth Rank Related Terms

Thank you for viewing the detailed overview of Patrys's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Patrys Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Patrys Ltd (ASX:PAB) » Definitions » Growth Rank
Comparable Companies
ASX:VBS ASX:BIT ASX:IXC ASX:1AD ASX:NSB ASX:ZLD ASX:CMB ASX:BGT ASX:ANR ASX:1AI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Website
https://www.patrys.com
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

Patrys Headlines